JP2019208502A - Lifestyle-related disease improvement or prevention food composition - Google Patents
Lifestyle-related disease improvement or prevention food composition Download PDFInfo
- Publication number
- JP2019208502A JP2019208502A JP2019098377A JP2019098377A JP2019208502A JP 2019208502 A JP2019208502 A JP 2019208502A JP 2019098377 A JP2019098377 A JP 2019098377A JP 2019098377 A JP2019098377 A JP 2019098377A JP 2019208502 A JP2019208502 A JP 2019208502A
- Authority
- JP
- Japan
- Prior art keywords
- food composition
- improving
- group
- preventing
- lifestyle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 235000013305 food Nutrition 0.000 title claims abstract description 52
- 201000010099 disease Diseases 0.000 title claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 22
- 230000006872 improvement Effects 0.000 title description 8
- 230000002265 prevention Effects 0.000 title description 5
- DPCMZUHKNHLUKT-UHFFFAOYSA-N OC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 Chemical compound OC=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 DPCMZUHKNHLUKT-UHFFFAOYSA-N 0.000 claims abstract description 44
- 230000003405 preventing effect Effects 0.000 claims abstract description 37
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 210000004185 liver Anatomy 0.000 claims abstract description 19
- 230000003908 liver function Effects 0.000 claims abstract description 18
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 15
- 206010000496 acne Diseases 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 47
- 235000008696 isoflavones Nutrition 0.000 claims description 47
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 25
- 206010012601 diabetes mellitus Diseases 0.000 claims description 12
- 210000003734 kidney Anatomy 0.000 claims description 11
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- 230000004761 fibrosis Effects 0.000 claims description 9
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 4
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 3
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 3
- 208000010706 fatty liver disease Diseases 0.000 claims description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 3
- 230000009471 action Effects 0.000 abstract description 16
- 206010023421 Kidney fibrosis Diseases 0.000 abstract description 6
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 6
- 235000009200 high fat diet Nutrition 0.000 description 37
- 238000012360 testing method Methods 0.000 description 29
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- 239000008103 glucose Substances 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 150000002515 isoflavone derivatives Chemical class 0.000 description 17
- 101000957724 Catostomus commersonii Corticoliberin-1 Proteins 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000001789 adipocyte Anatomy 0.000 description 10
- 230000007704 transition Effects 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 238000010827 pathological analysis Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000034659 glycolysis Effects 0.000 description 6
- 229930182470 glycoside Natural products 0.000 description 6
- -1 hydroxy isoflavone Chemical compound 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 235000021590 normal diet Nutrition 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000007410 oral glucose tolerance test Methods 0.000 description 5
- 210000001732 sebaceous gland Anatomy 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000037356 lipid metabolism Effects 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 3
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 3
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 244000294411 Mirabilis expansa Species 0.000 description 3
- 235000015429 Mirabilis expansa Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001949 daidzein Chemical class 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 235000006539 genistein Nutrition 0.000 description 3
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 3
- 229940045109 genistein Drugs 0.000 description 3
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000013536 miso Nutrition 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 235000015067 sauces Nutrition 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000012984 antibiotic solution Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000007240 daidzein Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 235000008466 glycitein Nutrition 0.000 description 2
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 2
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 229910052500 inorganic mineral Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Chemical class 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 235000019992 sake Nutrition 0.000 description 2
- 235000003687 soy isoflavones Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ZWSNUPOSLDAWJS-QNDFHXLGSA-N 6,7-dihydroxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one Chemical compound OC[C@H]1O[C@@H](Oc2ccc(cc2)-c2coc3cc(O)c(O)cc3c2=O)[C@H](O)[C@@H](O)[C@@H]1O ZWSNUPOSLDAWJS-QNDFHXLGSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- UIFFUZWRFRDZJC-UHFFFAOYSA-N Antimycin A1 Natural products CC1OC(=O)C(CCCCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-UHFFFAOYSA-N 0.000 description 1
- NQWZLRAORXLWDN-UHFFFAOYSA-N Antimycin-A Natural products CCCCCCC(=O)OC1C(C)OC(=O)C(NC(=O)c2ccc(NC=O)cc2O)C(C)OC(=O)C1CCCC NQWZLRAORXLWDN-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000015782 Electron Transport Complex III Human genes 0.000 description 1
- 108010024882 Electron Transport Complex III Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- XJTZHGNBKZYODI-UHFFFAOYSA-N Glycitin Natural products OCC1OC(Oc2ccc3OC=C(C(=O)c3c2CO)c4ccc(O)cc4)C(O)C(O)C1O XJTZHGNBKZYODI-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 241001559542 Hippocampus hippocampus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001113425 Iridaceae Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- UIFFUZWRFRDZJC-SBOOETFBSA-N antimycin A Chemical compound C[C@H]1OC(=O)[C@H](CCCCCC)[C@@H](OC(=O)CC(C)C)[C@H](C)OC(=O)[C@H]1NC(=O)C1=CC=CC(NC=O)=C1O UIFFUZWRFRDZJC-SBOOETFBSA-N 0.000 description 1
- PVEVXUMVNWSNIG-UHFFFAOYSA-N antimycin A3 Natural products CC1OC(=O)C(CCCC)C(OC(=O)CC(C)C)C(C)OC(=O)C1NC(=O)C1=CC=CC(NC=O)=C1O PVEVXUMVNWSNIG-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000011950 custard Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002910 effect on acne Effects 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 150000002272 genistein Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000008960 ketchup Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229940080817 rotenone Drugs 0.000 description 1
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 108091005054 serum thyroid hormone reducing factor Proteins 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000019583 umami taste Nutrition 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Abstract
Description
本発明は、生活習慣病の改善又は予防用食品組成物、肝臓及び腎臓の線維化の改善又は予防用食品組成物、肝機能改善用食品組成物、並びにニキビの改善又は予防用食品組成物に関する。 The present invention relates to a food composition for improving or preventing lifestyle-related diseases, a food composition for improving or preventing fibrosis of the liver and kidneys, a food composition for improving liver function, and a food composition for improving or preventing acne. .
近年、食生活の欧米化により、脂肪摂取量が上昇し、脂質異常症、高血圧、糖尿病、肥満などの生活習慣病が増加している。一般的に、生活習慣病の発生や予後に関する要因として、生活習慣、遺伝、環境が挙げられる。そして、生活習慣としては、食生活、運動習慣、休養、喫煙、飲酒などが挙げられる。 In recent years, with the westernization of dietary habits, fat intake has increased, and lifestyle-related diseases such as dyslipidemia, hypertension, diabetes and obesity are increasing. In general, lifestyle factors, heredity, and environment are factors related to the occurrence and prognosis of lifestyle-related diseases. And lifestyle habits include eating habits, exercise habits, rest, smoking, drinking alcohol and the like.
特許文献１では、高濃度にイソフラボンを含む原料を発酵させることで、ヒドロキシイソフラボンを効率的に製造することができること、得られたヒドロキシイソフラボンは優れた抗グリケーション作用を奏することが報告されている。特許文献１で製造されたヒドロキシイソフラボンは、8位がヒドロキシル化されたダイゼイン、ゲニステイン、グリシテインなどのイソフラボンである。 In Patent Document 1, it is reported that hydroxyisoflavone can be efficiently produced by fermenting a raw material containing isoflavone at a high concentration, and that the obtained hydroxyisoflavone exhibits an excellent anti-glycation action. . The hydroxyisoflavone produced in Patent Document 1 is an isoflavone such as daidzein, genistein, or glycitein that is hydroxylated at the 8-position.
また、特許文献２では、このようなヒドロキシイソフラボンを含む発酵イソフラボンが、未発酵のイソフラボンと比べて顕著に優れた脱毛防止作用を示す上に、環境ホルモン作用を示さないことが報告されている。特許文献２では脱毛防止作用が主に調査されており、それ以外の効果については具体的には示されていない。 Patent Document 2 reports that fermented isoflavones containing such hydroxyisoflavones exhibit a markedly superior hair loss preventing action as compared to unfermented isoflavones and do not exhibit an environmental hormone action. Patent Document 2 mainly investigates the hair loss prevention action, and does not specifically show other effects.
また、非特許文献１には、大豆イソフラボンが糖尿病などの各種疾患に対する効果について記載されており、大豆イソフラボンに含まれるゲニステインがβ細胞増殖に対する作用、インスリン分泌に対する作用などの糖尿病に対する効果を有することが記載されている。しかしながら、一般的に、血清インスリン濃度の上昇は、「膵臓への負担増加」を意味する。 Non-Patent Document 1 describes the effect of soy isoflavone on various diseases such as diabetes, and genistein contained in soy isoflavone has an effect on diabetes such as an action on β-cell proliferation and an action on insulin secretion. Is described. However, in general, an increase in serum insulin concentration means “an increased burden on the pancreas”.
本発明は、優れた生活習慣病の改善又は予防作用、肝臓及び腎臓の線維化の改善又は予防作用、肝機能改善作用、並びにニキビの改善又は予防作用を有する食品組成物を提供することを目的とする。 An object of the present invention is to provide a food composition having an excellent effect of improving or preventing lifestyle-related diseases, an effect of improving or preventing fibrosis of the liver and kidney, an effect of improving liver function, and an effect of improving or preventing acne. And
本発明者らは、上記目的を達成すべく鋭意研究を重ねた結果、ヒドロキシイソフラボンを含む発酵イソフラボンを、マウスに経口摂取させることで、高脂肪食による体重、血糖値、血清コレステロール値及び血清トリグリセリド値の上昇を抑制すること、更に糖尿病モデルマウスにおいて血糖値及びHbA1c値の上昇を抑制することを見出し、これは生活習慣病に対して著効を有することを示すものである。さらに、発酵イソフラボンにより肝臓及び腎臓の線維化が改善されることを見出した。また、マウスの肝機能に関わる血液検査結果から、発酵イソフラボンにより肝機能が改善されることを見出した。その上、発酵イソフラボンは、皮脂線細胞において炎症性サイトカインのTNFAの発現を抑制することが示されたので、これはニキビ(ざ瘡)に対して著効を有することを示すものである。 As a result of intensive studies to achieve the above object, the present inventors have orally ingested a fermented isoflavone containing hydroxyisoflavone into mice so that the body weight, blood glucose level, serum cholesterol level and serum triglyceride by high fat diet It was found that the increase of the blood glucose level and the increase of the blood glucose level and the HbA1c level were suppressed in the diabetes model mouse, and this shows that it has a significant effect on lifestyle-related diseases. Furthermore, it has been found that fermented isoflavones improve liver and kidney fibrosis. In addition, from the blood test results related to the liver function of mice, it was found that the liver function was improved by fermented isoflavones. In addition, fermented isoflavones have been shown to suppress the expression of the inflammatory cytokine TNFA in sebaceous cells, indicating that it has a marked effect on acne.
本発明は、これら知見に基づき、更に検討を重ねて完成されたものであり、次の生活習慣病の改善又は予防用食品組成物、肝臓及び／又は腎臓の線維化の改善又は予防用食品組成物、肝機能改善用食品組成物、並びにニキビの改善又は予防用食品組成物を提供するものである。 The present invention has been completed based on these findings, and has been completed. A food composition for improving or preventing the following lifestyle-related diseases, a food composition for improving or preventing fibrosis of the liver and / or kidneys. , A food composition for improving liver function, and a food composition for improving or preventing acne.
項１．下記式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩からなる群から選択される少なくとも１種を有効成分とする生活習慣病の改善又は予防用食品組成物。 Item 1. A food composition for improving or preventing lifestyle-related diseases comprising at least one selected from the group consisting of hydroxyisoflavones represented by the following formulas (1) to (5) and salts thereof as an active ingredient.
項２．前記生活習慣病が、糖尿病、インスリン抵抗性、脂質異常症、肥満、及び
脂肪肝からなる群から選択される少なくとも１種である、項１に記載の食品組成物。
項３．式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩からなる群から選択される少なくとも１種を有効成分とする肝臓及び／又は腎臓の線維化の改善又は予防用食品組成物。
項４．式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩からなる群から選択される少なくとも１種を有効成分とする肝機能改善用食品組成物。
項５．式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩からなる群から選択される少なくとも１種を有効成分とするニキビの改善又は予防用食品組成物。
項６．イソフラボン含有組成物の発酵物を有効成分とする、項１〜５のいずれか一項に記載の食品組成物。
Item 2. Item 2. The food composition according to Item 1, wherein the lifestyle-related disease is at least one selected from the group consisting of diabetes, insulin resistance, dyslipidemia, obesity, and fatty liver.
Item 3. A food composition for improving or preventing fibrosis of the liver and / or kidney, comprising at least one selected from the group consisting of hydroxyisoflavones represented by formulas (1) to (5) and salts thereof as an active ingredient.
Item 4. A food composition for improving liver function comprising as an active ingredient at least one selected from the group consisting of hydroxyisoflavones represented by formulas (1) to (5) and salts thereof.
Item 5. A food composition for improving or preventing acne comprising, as an active ingredient, at least one selected from the group consisting of hydroxyisoflavones represented by formulas (1) to (5) and salts thereof.
Item 6. Item 6. The food composition according to any one of Items 1 to 5, wherein the fermented product of the isoflavone-containing composition is an active ingredient.
ヒドロキシイソフラボン及びこれを含む発酵イソフラボンは、顕著に優れた生活習慣病の改善又は予防作用、肝臓及び腎臓の線維化の改善又は予防作用、肝機能改善作用、並びにニキビの改善又は予防作用を有するので、生活習慣病の改善又は予防用食品組成物、肝臓及び／又は腎臓の線維化の改善又は予防用食品組成物、肝機能改善用食品組成物、並びにニキビの改善又は予防用食品組成物の有効成分として有用である。 Hydroxyisoflavones and fermented isoflavones containing them have remarkably excellent effects of improving or preventing lifestyle-related diseases, improving or preventing liver and kidney fibrosis, improving liver function, and improving or preventing acne. Effectiveness of food composition for improving or preventing lifestyle-related diseases, food composition for improving or preventing fibrosis of liver and / or kidney, food composition for improving liver function, and food composition for improving or preventing acne Useful as an ingredient.
その上、ヒドロキシイソフラボン及びこれを含む発酵イソフラボンは、炎症作用及び環境ホルモン様作用を示さないため安全性において優れている。また、ヒドロキシイソフラボン及びこれを含む発酵イソフラボンは、天然由来成分であるので安全性が高い。 Moreover, hydroxyisoflavones and fermented isoflavones containing them are excellent in safety because they do not show inflammatory effects and environmental hormone-like effects. Moreover, since hydroxy isoflavone and fermented isoflavone containing this are natural origin components, they are highly safe.
以下、本発明について詳細に説明する。 Hereinafter, the present invention will be described in detail.
なお、本明細書において「含む(comprise)」とは、「本質的にからなる(essentially consist of)」という意味と、「のみからなる(consist of)」という意味をも包含する。 In the present specification, “comprise” includes the meaning of “essentially consist of” and the meaning of “consist of”.
本発明の生活習慣病の改善又は予防用食品組成物、肝臓及び／又は腎臓の線維化の改善又は予防用食品組成物、肝機能改善用食品組成物、並びにニキビの改善又は予防用食品組成物は、下記式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩からなる群から選択される少なくとも１種を有効成分とすることを特徴とする。 Food composition for improving or preventing lifestyle-related diseases of the present invention, food composition for improving or preventing liver and / or kidney fibrosis, food composition for improving liver function, and food composition for improving or preventing acne Is characterized by having at least one selected from the group consisting of hydroxyisoflavones represented by the following formulas (1) to (5) and salts thereof as an active ingredient.
式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩
式（１）で表されるヒドロキシイソフラボンは、ダイゼインの誘導体であって、8位(A環の8位)炭素にヒドロキシル基を備える化合物である。
Hydroxyisoflavones represented by the formulas (1) to (5) and salts thereof Hydroxyisoflavones represented by the formula (1) are derivatives of daidzein, which are hydroxyl groups at the 8-position (8-position of the A ring) carbon. It is a compound provided with.
式（２）で表されるヒドロキシイソフラボンは、ゲニステインの誘導体であって、8位(A環の8位)炭素にヒドロキシル基を備える化合物である。 The hydroxyisoflavone represented by the formula (2) is a derivative of genistein, which is a compound having a hydroxyl group at the 8-position carbon (8-position of the A ring).
式（３）で表されるヒドロキシイソフラボンは、グリシテインの誘導体であって、8位(A環の8位)炭素にヒドロキシル基を備える化合物である。 The hydroxyisoflavone represented by the formula (3) is a derivative of glycitein and is a compound having a hydroxyl group at the 8-position (8-position of the A ring) carbon.
式（４）で表されるヒドロキシイソフラボンは、ダイゼインの誘導体であって、6位(A環の6位)炭素にヒドロキシル基を備える化合物である。 The hydroxyisoflavone represented by the formula (4) is a derivative of daidzein and is a compound having a hydroxyl group at the 6-position (6-position of the A ring) carbon.
式（５）で表されるヒドロキシイソフラボンは、ダイゼインの誘導体であって、3'位(B環の3位)炭素にヒドロキシル基を備える化合物である。 The hydroxyisoflavone represented by the formula (5) is a derivative of daidzein and is a compound having a hydroxyl group at the 3′-position (3-position of ring B) carbon.
上記のようなヒドロキシイソフラボンは、イソフラボン配糖体(以下では配糖体と称することもある)からイソフラボンアグリコン(以下ではアグリコンと称することもある)を生成し、更に、このアグリコンをヒドロキシル化して得ることができる。ここで、ダイジン、グリシチン、ゲニスチンなどはA環7位に糖が結合した配糖体であり、この配糖体から糖を解離させることでダイゼイン、ゲニステイン、グリシテインなどのアグリコンが生成する。本明細書におけるイソフラボン類とは、イソフラボン配糖体、イソフラボンアグリコン及びヒドロキシイソフラボンを意味する。 The hydroxyisoflavone as described above is obtained by generating an isoflavone aglycone (hereinafter also referred to as an aglycone) from an isoflavone glycoside (hereinafter also referred to as a glycoside), and further hydroxylating the aglycone. be able to. Here, daidzin, glycitin, genistin and the like are glycosides in which a sugar is bonded to the 7-position of the A ring, and aglycones such as daidzein, genistein, and glycitein are produced by dissociating the sugar from this glycoside. The isoflavones in the present specification mean isoflavone glycosides, isoflavone aglycones and hydroxyisoflavones.
式（１）〜（５）で表されるヒドロキシイソフラボンの塩としては、例えば、ナトリウム、マグネシウム、カリウム、カルシウム、アルミニウム等の無機塩；メチルアミン、エチルアミン、エタノールアミン等の有機塩基との塩；リジン、オルニチン、アルギニン等の塩基性アミノ酸との塩及びアンモニウム塩が挙げられる。当該塩は、酸付加塩であってもよく、かかる塩としては、具体的には、塩酸、臭化水素酸、ヨウ化水素酸、硫酸、硝酸、リン酸等の鉱酸；ギ酸、酢酸、プロピオン酸、シュウ酸、マロン酸、リンゴ酸、酒石酸、フマル酸、コハク酸、乳酸、マレイン酸、クエン酸、メタンスルホン酸、エタンスルホン酸等の有機酸；アスパラギン酸、グルタミン酸等の酸性アミノ酸との酸付加塩が挙げられる。また、式（１）〜（５）で表されるヒドロキシイソフラボンには、その水和物、溶媒和物、結晶多形なども含まれる。 Examples of the salt of hydroxyisoflavone represented by the formulas (1) to (5) include inorganic salts such as sodium, magnesium, potassium, calcium and aluminum; salts with organic bases such as methylamine, ethylamine and ethanolamine; Examples thereof include salts with basic amino acids such as lysine, ornithine and arginine, and ammonium salts. The salt may be an acid addition salt. Specific examples of the salt include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid and other mineral acids; formic acid, acetic acid, Propionic acid, oxalic acid, malonic acid, malic acid, tartaric acid, fumaric acid, succinic acid, lactic acid, maleic acid, citric acid, methanesulfonic acid, ethanesulfonic acid and other organic acids; aspartic acid, glutamic acid and other acidic amino acids Examples include acid addition salts. The hydroxyisoflavones represented by the formulas (1) to (5) also include hydrates, solvates, crystal polymorphs, and the like.
本明細書において「式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩からなる群から選択される少なくとも１種」(以下では、これを本発明のヒドロキシイソフラボンと称することもある)とは、式（１）〜（５）で表されるヒドロキシイソフラボン及び式（１）〜（５）で表されるヒドロキシイソフラボンの塩の10種類の化合物から選択される少なくとも１種の化合物のことを意味する。 In the present specification, “at least one selected from the group consisting of hydroxyisoflavones represented by the formulas (1) to (5) and salts thereof” (hereinafter, this may be referred to as the hydroxyisoflavone of the present invention). ) Means at least one compound selected from 10 kinds of compounds of hydroxyisoflavones represented by formulas (1) to (5) and salts of hydroxyisoflavones represented by formulas (1) to (5) Means that.
本発明における式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩としては、単離又は精製された状態でない物(粗精製物)、及び単離又は精製された物のいずれも使用することができる。 As the hydroxyisoflavones represented by the formulas (1) to (5) and salts thereof in the present invention, any of an isolated or purified product (crude product) and an isolated or purified product are used. Can be used.
本発明における式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩は、自家調製品又は市販品を問わず使用することができる。自家調製する方法をとしては、発酵により生合成する方法、及び化学的に合成する方法が挙げられる。本発明の式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩は、中でも、イソフラボン含有組成物を発酵させて製造することが好ましい。本発明では、式（１）〜（５）で表されるヒドロキシイソフラボン及びそれらの塩を含む、イソフラボン含有組成物の発酵物それ自体を使用することもできる。そのようなイソフラボン含有組成物の発酵物は、東洋発酵株式会社より「UNIFINE (登録商標)」として販売されている。 The hydroxyisoflavones and salts thereof represented by the formulas (1) to (5) in the present invention can be used regardless of whether they are self-prepared products or commercial products. Examples of the self-preparing method include a method of biosynthesis by fermentation and a method of chemical synthesis. The hydroxyisoflavones and salts thereof represented by the formulas (1) to (5) of the present invention are preferably produced by fermenting an isoflavone-containing composition. In the present invention, a fermented product of an isoflavone-containing composition containing the hydroxyisoflavones represented by the formulas (1) to (5) and salts thereof can be used. A fermented product of such an isoflavone-containing composition is sold as “UNIFINE (registered trademark)” by Toyo Fermentation Co., Ltd.
本発明におけるイソフラボン含有組成物は、イソフラボン類を含有する組成物のことであり、通常、イソフラボン配糖体及びイソフラボンアグリコン、特にイソフラボン配糖体を多く含有する。イソフラボン含有組成物に含まれるイソフラボン類の量は、特に制限されず、好ましくは10〜100質量%、より好ましくは25〜99質量%、更に好ましくは35〜90質量%、特に好ましくは40〜80質量%である。このようにイソフラボン含有組成物中のイソフラボン類の含有量が高い場合は、発酵によりヒドロキシイソフラボンを高濃度で得ることができる。 The isoflavone-containing composition in the present invention is a composition containing isoflavones, and usually contains a large amount of isoflavone glycosides and isoflavone aglycones, particularly isoflavone glycosides. The amount of the isoflavones contained in the isoflavone-containing composition is not particularly limited, preferably 10 to 100% by mass, more preferably 25 to 99% by mass, still more preferably 35 to 90% by mass, and particularly preferably 40 to 80%. % By mass. Thus, when the content of isoflavones in the isoflavone-containing composition is high, hydroxyisoflavone can be obtained at a high concentration by fermentation.
上記イソフラボン含有組成物としては、イソフラボン類が濃縮されて含有された植物抽出物が挙げられる。植物抽出物を得るための植物としては、豆科植物、バラ科植物、アヤメ科植物、桑科植物、ヒユ科植物などが挙げられ、これらの中では他の植物に比べてイソフラボン類の含有量が多いことから豆科植物が好ましい。 Examples of the isoflavone-containing composition include plant extracts containing concentrated isoflavones. Plants for obtaining plant extracts include leguminous plants, rose family plants, iris family plants, mulberry family plants, and amaranth family plants. Among them, the content of isoflavones compared to other plants Therefore, legumes are preferable.
イソフラボン含有組成物の発酵は、公知の方法、例えば、特許文献１(特許第５３１８３３９号公報)に記載の方法に従い実施することができる。 The fermentation of the isoflavone-containing composition can be carried out according to a known method, for example, the method described in Patent Document 1 (Japanese Patent No. 5318339).
本発明におけるイソフラボン含有組成物の発酵物としては、発酵により得られた状態のままの物、及び発酵後に抽出処理、濃縮処理、濾過処理、乾燥処理、滅菌処理、pH調整、脱臭処理、脱色処理等の処理を行った物のいずれも使用することができる。 As the fermented product of the isoflavone-containing composition in the present invention, a product as it is obtained by fermentation, and after fermentation, extraction treatment, concentration treatment, filtration treatment, drying treatment, sterilization treatment, pH adjustment, deodorization treatment, decolorization treatment Any of the processed materials can be used.
本発明のヒドロキシイソフラボン及びこれを含む発酵イソフラボンは、特許文献２(特開２０１８−５２９２８号公報)に示されているように、炎症作用及び環境ホルモン様作用(性ホルモン作用、特にエストロゲン作用)を示さないため安全性において優れている。さらに、本発明のヒドロキシイソフラボン及びこれを含む発酵イソフラボンは、天然由来成分であるので安全性が高い。 The hydroxyisoflavone of the present invention and the fermented isoflavone containing the same have an inflammatory action and an environmental hormone-like action (sex hormone action, particularly estrogen action) as shown in Patent Document 2 (Japanese Patent Laid-Open No. 2018-52928). Since it is not shown, it is excellent in safety. Furthermore, since the hydroxyisoflavone of the present invention and the fermented isoflavone containing the same are naturally derived components, safety is high.
食品組成物としては哺乳動物(ヒトを含む)が摂取できるあらゆる飲食品が含まれ、例えば、乳製品；発酵食品(ヨーグルト、チーズ等)；飲料類(コーヒー、ジュース、ココア、茶飲料、スポーツドリンク、栄養ドリンクのような清涼飲料、乳飲料、乳酸菌飲料、乳酸菌入り飲料、ヨーグルト飲料、炭酸飲料、日本酒、洋酒、果実酒のような酒等)；スプレッド類(カスタードクリーム等)；ペースト類(フルーツペースト等)；洋菓子類(チョコレート、ドーナツ、パイ、シュークリーム、ガム、グミ、ゼリー、キャンデー、クッキー、ケーキ、プリン、ビスケット等)；氷菓類(アイスクリーム、アイスキャンデー、シャーベット等)；食品類(カレー、牛丼、雑炊、味噌汁、スープ、ミートソース、パスタ、漬物、ジャム、ハム、ソーセージ、ベーコン等)；調味料類(ドレッシング、ふりかけ、旨味調味料、スープの素、味噌、醤油、ソース、ケチャップ、オイスターソース等)などが挙げられる。 The food composition includes all foods and drinks that can be consumed by mammals (including humans), such as dairy products; fermented foods (yogurt, cheese, etc.); beverages (coffee, juice, cocoa, tea drinks, sports drinks) , Soft drinks such as energy drinks, milk drinks, lactic acid bacteria drinks, drinks containing lactic acid bacteria, yogurt drinks, carbonated drinks, sakes such as sake, western liquor, fruit liquor); spreads (such as custard cream); pastes (fruit) Pastes (chocolate, donut, pie, cream puff, gum, gummi, jelly, candy, cookies, cake, pudding, biscuits, etc.); Ice confectionery (ice cream, popsicle, sorbet, etc.); Foods (curry) , Beef bowl, miso soup, miso soup, soup, meat sauce, pasta, pickles, jam, ham, sausage, bacon, etc.) Seasonings (dressing, sprinkle, umami seasoning, soup stock, miso, soy sauce, sauce, ketchup, oyster sauce, etc.).
食品組成物の製法も特に限定されず、適宜公知の方法に従うことができる。 The production method of the food composition is not particularly limited, and can be appropriately followed by a known method.
食品組成物としては、健康食品、機能性食品、栄養補助食品、サプリメント、保健用食品、特定保健用食品、栄養機能食品、機能性表示食品なども挙げられる。サプリメントとして使用する際の投与単位形態については特に限定されず適宜選択できるが、例えば、錠剤、カプセル剤、顆粒剤、液剤、散剤等が挙げられる。 Examples of food compositions include health foods, functional foods, nutritional supplements, supplements, health foods, foods for specified health use, functional nutrition foods, and functional label foods. The dosage unit form for use as a supplement is not particularly limited and may be appropriately selected. Examples thereof include tablets, capsules, granules, liquids, and powders.
また、食品組成物としては、生活習慣病の改善又は予防作用、肝臓及び腎臓の線維化の改善又は予防作用、肝機能改善作用、及びニキビの改善又は予防作用を付与する添加剤についての意味も包含するものである。 In addition, as a food composition, there is also a meaning for an additive that imparts an action for improving or preventing lifestyle-related diseases, an action for improving or preventing fibrosis of the liver and kidney, an action for improving liver function, and an action for improving or preventing acne. It is included.
食品組成物には、必要に応じて、賦形剤、ビタミン類、ミネラル類、フラボノイド類、キノン類、ポリフェノール類、アミノ酸、核酸、必須脂肪酸、清涼剤、結合剤、甘味料、崩壊剤、滑沢剤、着色料、香料、安定化剤、防腐剤、徐放調整剤、界面活性剤、光沢剤、溶解剤、湿潤剤等を配合することができる。 The food composition may contain excipients, vitamins, minerals, flavonoids, quinones, polyphenols, amino acids, nucleic acids, essential fatty acids, cooling agents, binders, sweeteners, disintegrants, lubricants as necessary. A lot of additives, coloring agents, fragrances, stabilizers, preservatives, sustained release regulators, surfactants, brighteners, solubilizers, wetting agents and the like can be blended.
食品組成物に含まれる本発明のヒドロキシルイソフラボンの割合は、例えば、0.01〜99質量%、0.1〜80質量%、1〜70質量%などが挙げられる。 Examples of the proportion of the hydroxyl isoflavone of the present invention contained in the food composition include 0.01 to 99% by mass, 0.1 to 80% by mass, and 1 to 70% by mass.
食品組成物の摂取量は、摂取者の体重、年齢、性別、症状などの種々の条件に応じて適宜設定することができる。 The intake amount of the food composition can be appropriately set according to various conditions such as the body weight, age, sex, and symptoms of the intake person.
後述する実施例で示すように、本発明者らは、マウスに本発明のヒドロキシイソフラボンを経口摂取させることで、高脂肪食による体重、血糖値、血清コレステロール値及び血清トリグリセリド値の上昇を抑制し、更に糖尿病モデルマウスにおいて血糖値及びHbA1c値の上昇を抑制することを見出したことから、生活習慣病に対する改善又は予防作用が期待できる。さらに、本発明のヒドロキシイソフラボンの摂取により肝臓及び腎臓の線維化の改善が観察された。また、マウスの糖負荷試験では、本発明のヒドロキシイソフラボンの摂取により血糖値の低下が観察されたことから、インスリン抵抗性に対する効果が期待できる。さらに、マウスの肝機能及び脂質代謝に関わる血液検査結果から、本発明のヒドロキシイソフラボンによる肝機能及び脂質代謝の改善が観察された。その上、本発明のヒドロキシイソフラボンは、皮脂線細胞において炎症性サイトカインのTNFA (TNF-α)の発現を抑制することを見出したことから、ニキビ(ざ瘡)に対する改善又は予防作用が期待できる。 As shown in the examples described below, the present inventors orally ingested the hydroxyisoflavone of the present invention in mice, thereby suppressing an increase in body weight, blood glucose level, serum cholesterol level and serum triglyceride level due to a high fat diet. Furthermore, since it was found that the increase in blood glucose level and HbA1c level was suppressed in diabetes model mice, an improvement or prevention action against lifestyle-related diseases can be expected. In addition, improvement of liver and kidney fibrosis was observed by ingestion of the hydroxyisoflavone of the present invention. Moreover, in the glucose tolerance test of mice, a decrease in blood glucose level was observed by ingestion of the hydroxyisoflavone of the present invention, so that an effect on insulin resistance can be expected. Furthermore, the improvement of liver function and lipid metabolism by the hydroxyisoflavone of the present invention was observed from blood test results related to liver function and lipid metabolism in mice. Moreover, since the hydroxyisoflavone of the present invention has been found to suppress the expression of the inflammatory cytokine TNFA (TNF-α) in sebaceous cells, it can be expected to improve or prevent acne (acne).
そのため、本発明のヒドロキシイソフラボンは、顕著に優れた生活習慣病の改善又は予防作用、肝臓及び腎臓の線維化の改善又は予防作用、肝機能改善作用、並びにニキビの改善又は予防作用を有するので、生活習慣病の改善又は予防用食品組成物、肝臓及び／又は腎臓の線維化の改善又は予防用食品組成物、肝機能改善用食品組成物、並びにニキビの改善又は予防用食品組成物の有効成分として好適に使用することができる。 Therefore, the hydroxyisoflavone of the present invention has a markedly excellent improvement or prevention of lifestyle-related diseases, improvement or prevention of fibrosis of the liver and kidney, improvement of liver function, and improvement or prevention of acne. Active ingredient of food composition for improving or preventing lifestyle diseases, food composition for improving or preventing fibrosis of liver and / or kidney, food composition for improving liver function, and food composition for improving or preventing acne Can be suitably used.
ここで、生活習慣病としては、特に制限されず、例えば、糖尿病(特に2型糖尿病)、インスリン抵抗性、脂質異常症、肥満、脂肪肝などが挙げられる。 Here, the lifestyle-related diseases are not particularly limited, and examples thereof include diabetes (particularly type 2 diabetes), insulin resistance, dyslipidemia, obesity, fatty liver and the like.
以下、本発明を更に詳しく説明するため実施例を挙げる。しかし、本発明はこれら実施例等になんら限定されるものではない。 Examples are given below to illustrate the present invention in more detail. However, the present invention is not limited to these examples.
以下の実験で使用するUnifine (東洋発酵株式会社)は、イソフラボンを含む大豆エキスを麹菌で発酵した発酵素材であり、本発明の8-OH体イソフラボンを7.7%含有する物である。 Unifine (Toyo Fermentation Co., Ltd.) used in the following experiments is a fermentation material obtained by fermenting soybean extract containing isoflavone with koji mold, and contains 7.7% of the 8-OH isoflavone of the present invention.
＜実験方法＞
１．高脂肪食(HFD)試験
Unifineは、日本クレア株式会社(Tokyo, Japan)に依頼し、HFD-32に2%の濃度で混餌した。血糖値は、ニプロフリースタイルフリーダムライト(Nipro, Osaka, Japan)を用いて測定した。血清はヘマトクリット管を用いて血液を採取し、12,000rpm にて分離後、コレステロールワコー・トリグリセリドワコー(FUJIFILM Wako Pure Chemical, Osaka, Japan)を用いて、経時的に測定した。糖負荷試験(OGTT: oral glucose tolerancetest)は、同様に6週間のHFD負荷を行った後、300 mg/mlグルコースを100μl経口投与することにより行い、継時的に上述の血糖値測定を行った。
<Experiment method>
1. High fat diet (HFD) test
Unifine was commissioned by Japan Claire Co., Ltd. (Tokyo, Japan) and mixed with HFD-32 at a concentration of 2%. The blood glucose level was measured using Nipro Freestyle Freedom Light (Nipro, Osaka, Japan). Serum was collected using a hematocrit tube, separated at 12,000 rpm, and then measured over time using cholesterol wako triglyceride wako (FUJIFILM Wako Pure Chemical, Osaka, Japan). The glucose tolerance test (OGTT: oral glucose tolerance test) was similarly carried out by orally administering 300 mg / ml glucose after 100 weeks of HFD loading, and the blood glucose level was measured continuously. .
２．KK-Ayマウス試験
8週齢雄KK-Ayマウスは、日本クレア株式会社(Tokyo, Japan)より搬入した。1週間の馴化の後、普通食(CRF-1：オリエンタル酵母株式会社)を対照群として、CRF-1に2%のUnifineを混餌した試料を連日8週間摂取させ、体重及び平常時血糖値を測定した。HbA1c値は、8週間経過後、麻酔下で心採血を行い、抗凝固剤として10%EDTAを500μlの血液に対して10μl添加し、冷蔵保存した。これらのサンプルは、株式会社オリエンタルバイオサービスに依頼し、HbA1c値を測定した。
2. KK-Ay mouse test
Eight-week-old male KK-Ay mice were transferred from Nippon Claire Co., Ltd. (Tokyo, Japan). After acclimation for 1 week, with a normal diet (CRF-1: Oriental Yeast Co., Ltd.) as a control group, a sample of CRF-1 mixed with 2% Unifine was ingested daily for 8 weeks, and body weight and normal blood glucose level were measured. It was measured. Regarding the HbA1c value, after 8 weeks, heart blood was collected under anesthesia, 10 μl of 10% EDTA was added as an anticoagulant to 500 μl of blood, and stored refrigerated. These samples were requested from Oriental Bio Service Co., Ltd., and HbA1c values were measured.
３．低容量ストレプトゾトシン(STZ)誘導糖尿病モデルマウス試験
個体1匹あたり、100 mg/kgの濃度で15週齢BL6マウスにストレプトゾトシンを腹腔内注射した。平常時血糖値が300 mg/dl以上になることで、糖尿病の病態が形成されたと判断した。普通食(CRF-1)を対照群として、CRF-1に2%のUnifineを混餌した試料を連日摂取させ、体重及び平常時血糖値を測定した。
3. Low volume streptozotocin (STZ) -induced diabetes model mouse test Streptozotocin was injected intraperitoneally into BL6 mice at 15 weeks of age at a concentration of 100 mg / kg per individual. It was judged that a diabetic condition was formed when the normal blood glucose level was 300 mg / dl or higher. Using a normal diet (CRF-1) as a control group, a sample of CRF-1 mixed with 2% Unifine was ingested every day, and body weight and normal blood glucose level were measured.
４．3T3-L1脂肪細胞分化試験
マウス脂肪細胞前駆細胞は、10%牛胎児血清(FCS)及びペニシリン・ストレプトマイシン・アムホテリシンB (抗生物質溶液)を含むDMEMにて培養を行った。脂肪細胞への分化は、10μg/mlインスリン、2.5μMデキサメタゾン、10μg/ml 3-イソブチル-1-メチルキサンチン(IBMX)を終濃度として加えた培地に、40μg/mlのUnifineを含むように添加し、隔日に培地を交換して、経過観察を行った。
4. 3T3-L1 Adipocyte Differentiation Test Mouse adipocyte progenitor cells were cultured in DMEM containing 10% fetal calf serum (FCS) and penicillin / streptomycin / amphotericin B (antibiotic solution). For differentiation into adipocytes, add 10 μg / ml insulin, 2.5 μM dexamethasone, 10 μg / ml 3-isobutyl-1-methylxanthine (IBMX) as a final concentration to contain 40 μg / ml Unifine. The culture medium was changed every other day and the follow-up was performed.
５．SZ-95皮脂腺細胞分化試験
SZ-95:ヒト皮脂腺細胞株は、デッサウ医療センター(ドイツ)から輸入し、Sebomed basal medium (Biochrom, Berlin, Germany)に、10%FCS、抗生物質溶液、ヒト組換え型EGF (Peprotech)(終濃度：5 ng/ml)を添加して培養した。10μg/ml大腸菌LPS (ナカライテスク株式会社, Kyoto, Japan)の刺激の有無の30分前に、40μg/mlのUnifineを含むように添加し、LPS添加の24時間後に、細胞をセパゾール(RNA抽出液)で可溶化した。
5. SZ-95 Sebaceous gland cell differentiation test
SZ-95: Human sebaceous gland cell line was imported from Dessau Medical Center (Germany), and sebomed basal medium (Biochrom, Berlin, Germany) was imported into 10% FCS, antibiotic solution, human recombinant EGF (Peprotech) (final). Concentration: 5 ng / ml) was added and cultured. 10 μg / ml E. coli LPS (Nacalai Tesque, Kyoto, Japan) was added 30 minutes before or after stimulation to contain 40 μg / ml Unifine, and cells were separated by Sephazol (RNA extraction) 24 hours after LPS addition. Solution).
６．定量的PCR (qPCR)
常法によりtotal RNAを調製し、1 gを逆転写反応した。次に、Piko real system (Thermo fisher Scientific)を用いて、定量的PCR解析を行った。用いたプライマーペアは以下のとおりである。
hTNFA
5'-ATGAGCACTGAAAGCATGATCC-3' (配列番号１)
5'-GAGGGCTGATTAGAGAGAGGTC-3' (配列番号２)
hGAPDH
5'-ACCCACTCCTCCACCTTTG-3' (配列番号３)
5'-CTCTTGTGCTCTTGCTGGG-3' (配列番号４)
6). Quantitative PCR (qPCR)
Total RNA was prepared by a conventional method, and 1 g was reverse-transcribed. Next, quantitative PCR analysis was performed using Piko real system (Thermo fisher Scientific). The primer pairs used are as follows.
hTNFA
5'-ATGAGCACTGAAAGCATGATCC-3 '(SEQ ID NO: 1)
5'-GAGGGCTGATTAGAGAGAGGTC-3 '(SEQ ID NO: 2)
hGAPDH
5'-ACCCACTCCTCCACCTTTG-3 '(SEQ ID NO: 3)
5'-CTCTTGTGCTCTTGCTGGG-3 '(SEQ ID NO: 4)
７．フラックスアナライザー試験
C2C12細胞は、10%牛胎仔血清(fetal bovine serum: FBS)及び抗生物質を含むhigh glucose DMEM(ナカライテスク株式会社)により継代しながら培養を行った。
7). Flux analyzer test
C2C12 cells were cultured while being passaged with high glucose DMEM (Nacalai Tesque) containing 10% fetal bovine serum (FBS) and antibiotics.
専用の24穴プレートに30,000細胞の濃度でC2C12細胞を播種し、培養を行った。20μg/mlのUnifine (発酵イソフラボン)又は未発酵イソフラボンの存在下で、C2C12細胞を48時間前処理した。その後、細胞は、10 mMグルコース、1 mMピルビン酸、及び2 mMグルタミンが添加されたシーホース培地を用いてインキュベートした。Rotenone (Rot：Complex I阻害薬)、Antimycin A (AA：Complex III阻害薬)、2-deoxyglucose (2-DG：解糖系阻害薬)をそれぞれ終濃度1μM (Rot)、1μM (AA)、10 mM (2-DG)となるように調製し、Glycolysis rate assay kit用にプログラムしてフラックスアナライザー(Agilent Technologies)により解析を行った。 C2C12 cells were seeded at a concentration of 30,000 cells in a dedicated 24-well plate and cultured. C2C12 cells were pretreated for 48 hours in the presence of 20 μg / ml Unifine (fermented isoflavone) or unfermented isoflavone. The cells were then incubated with Seahorse medium supplemented with 10 mM glucose, 1 mM pyruvate, and 2 mM glutamine. Rotenone (Rot: Complex I inhibitor), Antimycin A (AA: Complex III inhibitor), 2-deoxyglucose (2-DG: glycolytic inhibitor), respectively, at final concentrations of 1 μM (Rot), 1 μM (AA), 10 Prepared to be mM (2-DG), programmed for Glycolysis rate assay kit, and analyzed with a flux analyzer (Agilent Technologies).
８．統計処理
有意差の検定はstudent's unpaird t-testを用いて、多検体比較はDunnet-test又はTukey-testを用いた。p<0.05の場合は有意であると判定した。
8). Statistical processing Student's unpaired t-test was used for the test of significant difference, and Dunnet-test or Tukey-test was used for multi-sample comparison. When p <0.05, it was determined to be significant.
＜結果＞
１．HFD試験
HFD試験の結果を図１〜４及び表１に示す。
<Result>
1. HFD test
The results of the HFD test are shown in FIGS.
HFD群は、普通食を給餌したNormal Diet:ND群に比べ、明確に体重増加、並びに平常時血糖値、平常時血清トリグリセリド値、及び血清コレステロール値のいずれのパラメーターも時間経過とともに増加したのに対して、HFDに混餌した2% Unifine (以下、HFD+Unifine群)は、顕著に体重増加を防止し、各パラメーターにおいて良好な成績を示した(図１)。 Compared to the Normal Diet: ND group fed the normal diet, the HFD group clearly gained weight, and the parameters of normal blood glucose, normal serum triglyceride, and serum cholesterol increased over time. On the other hand, 2% Unifine (hereinafter referred to as HFD + Unifine group) fed with HFD significantly prevented weight gain and showed good results in each parameter (FIG. 1).
また、それぞれの餌で6週間飼育した後、剖検した。その結果、体重に比例するように、HFD群ではND群に比べて明らかに内臓脂肪が形成されていたのに対して、HFD+Unifine群では腸間膜脂肪組織及び精巣上体脂肪組織のいずれも縮小していた(図２)。 In addition, each food was reared for 6 weeks and then necropsied. As a result, the visceral fat was clearly formed in the HFD group as compared with the ND group as compared with the body weight, whereas in the HFD + Unifine group, either the mesenteric adipose tissue or the epididymal adipose tissue. (Figure 2).
6週間のHFD試験を行った後、肝臓の一部は、病理解析に供した。ND群は正常な組織像を示したのに対して(図３Ａ、Ｄ、Ｇ)、HFD群は肝組織内に白抜けした領域(脂肪)を多領域に観察した(図３Ｂ、Ｅ、Ｈ)。これに対し、HFD＋Unifine群は、ND群と同様、ほぼ正常な組織像を認めた(図３Ｃ、Ｆ、Ｉ)。 After 6 weeks of HFD testing, a portion of the liver was subjected to pathological analysis. The ND group showed normal tissue images (FIGS. 3A, 3D, 3G), while the HFD group observed white areas (fats) in the liver tissue in multiple areas (FIGS. 3B, 3E, 3H). ). In contrast, in the HFD + Unifine group, almost normal tissue images were recognized as in the ND group (FIGS. 3C, F, and I).
6週間のHFD試験を行った後、脂肪組織の一部は、病理解析に供した。ND群は正常な組織像を示したのに対して(図４Ａ)、HFD群は肥大化した脂肪細胞を多領域に観察した(図４Ｂ)。これに対し、HFD＋Unifine群は、ND群ほどは改善していなかったが、脂肪細胞の直径測定試験により、有意に小型化した(図４Ｃ、Ｄ)。 After 6 weeks of HFD testing, a portion of the adipose tissue was subjected to pathological analysis. The ND group showed normal histology (FIG. 4A), whereas the HFD group observed enlarged adipocytes in multiple regions (FIG. 4B). In contrast, the HFD + Unifine group did not improve as much as the ND group, but was significantly reduced in size by the fat cell diameter measurement test (FIGS. 4C and 4D).
また、病理解析に供した肝臓の一部について、HE染色、アザン染色及びPSA染色を行った(図５)。HFD群において、アザン染色により、全体的に青色に染まっており、コラーゲンなどの膠原繊維質が増加していると考えられる。これに対して、HFD+Unifine群は青色に染色されていなかった。PAS染色は、グリコーゲンが染色されており、HFD群において、濃く染色された部分がまだらになり、薄く染色される縞状の像が認められ、HFD+Unifine群ではそれは認められなかった。 Moreover, HE staining, Azan staining, and PSA staining were performed on a part of the liver subjected to pathological analysis (FIG. 5). In the HFD group, it is dyed blue overall due to Azan staining, and it is thought that collagen fibers such as collagen are increasing. In contrast, the HFD + Unifine group was not stained blue. In PAS staining, glycogen was stained, and in the HFD group, the darkly stained portion became mottled, and a striped image that was lightly stained was observed, but not in the HFD + Unifine group.
腎臓の一部についても、病理解析に供し、アザン染色及びPAS染色を行った(図６)。HFD群において、アザン染色により、腎皮質側の腎糸球体が濃青色に染色されていたが、これはHFD+Unifine群においては観察されなかった。また、PAS染色から、HFD群のみ薄く染色された。 A part of the kidney was also subjected to pathological analysis and subjected to Azan staining and PAS staining (FIG. 6). In the HFD group, renal glomeruli on the renal cortex side were stained dark blue by Azan staining, but this was not observed in the HFD + Unifine group. Moreover, only the HFD group was stained lightly from PAS staining.
剖検時に心採血を行い、肝機能マーカーと脂質代謝マーカーについて、血液検査を行った。その結果、各肝機能検査値及び脂質代謝検査値は、HFDによって大きく悪化し、そこへUnifineが加わったことで大きく改善した(表１)。 Cardiac blood was collected at necropsy, and blood tests were performed for liver function markers and lipid metabolism markers. As a result, each liver function test value and lipid metabolism test value were greatly deteriorated by HFD, and it was greatly improved by the addition of Unifine (Table 1).
２．OGTT試験
上記HFD試験の結果から、発酵イソフラボンが抗糖尿病作用を有することが強く示唆されたので、次にOGTT試験を行った。結果を図７に示す。
2. OGTT Test Since the results of the above HFD test strongly suggested that fermented isoflavones have an anti-diabetic action, the OGTT test was performed next. The results are shown in FIG.
その結果、異なる2つのマウス種(ddYとC57/BL6N)で、同様にHFDは体重増加を示したのに対し、HFD+Unifine群は有意に体重増加を予防した(図７Ａ)。この条件下で、Unifineは耐糖能を示し、糖負荷後30分の血糖値の最高血中濃度、及びその後の速やかな血糖値の低下を示した(図７Ｂ)。 As a result, in two different mouse species (ddY and C57 / BL6N), HFD similarly showed an increase in body weight, whereas the HFD + Unifine group significantly prevented an increase in body weight (FIG. 7A). Under this condition, Unifine showed glucose tolerance, showing a maximum blood glucose level 30 minutes after glucose loading, and then a rapid decrease in blood glucose level (FIG. 7B).
３．KK-Ayマウス試験
次に、2型糖尿病モデルであるKK-Ayマウスを用いて、Unifineの効果を調べた。Unifineは、通常食：CRF-1に2%の濃度で混餌し、8週間飼育した。結果を図８に示す。
3. KK-Ay mouse test Next, the effect of Unifine was examined using a KK-Ay mouse, which is a type 2 diabetes model. Unifine was fed on a normal diet: CRF-1 at a concentration of 2% and raised for 8 weeks. The results are shown in FIG.
KK-Ayマウスは、CRF-1により体重増加を認めたのに対し、Unifineを混餌したCRF-1で飼育すると、その増加は穏やかになった(図８Ａ)。また、経時的に平常時血糖値を測定したところ、およそ1週間経過後ほどから顕著にCRF-1で飼育したマウスは高血糖を示したのに対し、Unifineを混餌したCRF-1で飼育するとほぼ200 mg/dl以下で推移した(図８Ｂ)。また、およそ1ヶ月前の血糖状態を反映するHbA1c値は、Unifineにより顕著に抑制された(図８Ｃ)。 In KK-Ay mice, weight gain was observed with CRF-1, whereas when bred with CRF-1 fed with Unifine, the increase became mild (FIG. 8A). In addition, when the normal blood glucose level was measured over time, the mice bred with CRF-1 markedly after about 1 week showed hyperglycemia, whereas when bred with CRF-1 mixed with Unifine, It changed at 200 mg / dl or less (FIG. 8B). Moreover, the HbA1c value reflecting the blood glucose state about one month ago was remarkably suppressed by Unifine (FIG. 8C).
４．低容量ストレプトゾトシン誘導糖尿病モデルマウス試験
低容量ストレプトゾトシン誘導糖尿病モデルマウスを用いて、Unifineの効果を調べた。Unifineは、通常食：CRF-1に2%の濃度で混餌し飼育した。結果を図９に示す。
4). Low Volume Streptozotocin-Induced Diabetes Model Mouse Test The effect of Unifine was examined using a low volume streptozotocin-induced diabetes model mouse. Unifine was fed with a normal diet: CRF-1 at a concentration of 2%. The results are shown in FIG.
経時的に平常時血糖値を測定したところ、STZ投与しCRF-1で飼育したマウスは高血糖を示したのに対し、STZ投与しUnifineを混餌したCRF-1で飼育すると血糖値は低下していた(図９Ａ)。また、全ての群で64日間(およそ9週間)体重減少が認められないので、２型糖尿病と判断された(図９Ｂ)。 Normal blood glucose levels were measured over time. STZ-administered mice bred with CRF-1 showed hyperglycemia, whereas STZ-administered CRF-1 mixed with Unifine decreased blood glucose levels. (FIG. 9A). Moreover, since no weight loss was observed in all groups for 64 days (approximately 9 weeks), it was judged as type 2 diabetes (FIG. 9B).
５．培養細胞へのUnifineの効果
脂肪細胞分化試験及び皮脂腺細胞分化試験を行った。その結果を図１０及び１１に示す。
5. Effect of Unifine on cultured cells An adipocyte differentiation test and a sebaceous gland cell differentiation test were performed. The results are shown in FIGS.
脂肪細胞分化系では、Unifineは脂肪細胞分化を抑制した(図１０)。そこで、皮脂腺細胞の炎症モデルを用いて調べたところ、LPSによって炎症性サイトカインであるTNFAの発現が著しく亢進し、これに対してUnifineは顕著に抑制作用を示した(図１１)。 In the adipocyte differentiation system, Unifine suppressed adipocyte differentiation (FIG. 10). Then, when examined using an inflammation model of sebaceous gland cells, the expression of TNFA, which is an inflammatory cytokine, was remarkably increased by LPS, whereas Unifine showed a markedly inhibitory action (FIG. 11).
６．Glycolysis rateアッセイ
Glycolysis rateアッセイを行った。その結果を図１２に示す。
6). Glycolysis rate assay
Glycolysis rate assay was performed. The result is shown in FIG.
Basal Glycolysisは、未発酵イソフラボンでは影響がなく、発酵イソフラボンにおいてのみ、ECARの上昇が認められ、glycoPER値は有意に亢進していた。また、Compensatory GlycolysisのglycoPER値も発酵イソフラボンにおいてのみ有意に亢進していた。 Basal Glycolysis had no effect on unfermented isoflavones, only in fermented isoflavones, an increase in ECAR was observed, and the glycoPER value was significantly increased. In addition, the glycoPER value of Compensatory Glycolysis was significantly increased only in fermented isoflavones.
Claims (6)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018103784 | 2018-05-30 | ||
| JP2018103784 | 2018-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2019208502A true JP2019208502A (en) | 2019-12-12 |
Family
ID=68843940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019098377A Pending JP2019208502A (en) | 2018-05-30 | 2019-05-27 | Lifestyle-related disease improvement or prevention food composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2019208502A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008056576A (en) * | 2006-08-29 | 2008-03-13 | Toyo Hakko:Kk | Antiglycation composition, food, drink, additive for food and drink, cosmetic composition and pharmaceutical composition containing the same and method for producing hydroxyisoflavone |
| WO2009026657A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Flavonoid ppar agonists |
-
2019
- 2019-05-27 JP JP2019098377A patent/JP2019208502A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008056576A (en) * | 2006-08-29 | 2008-03-13 | Toyo Hakko:Kk | Antiglycation composition, food, drink, additive for food and drink, cosmetic composition and pharmaceutical composition containing the same and method for producing hydroxyisoflavone |
| WO2009026657A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Flavonoid ppar agonists |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5521027B2 (en) | Equol concentration regulator | |
| US20050256178A1 (en) | Novel nutraceutical compositions comprising boitin | |
| KR20190090362A (en) | A composition for imobesity containing dicaffeoylquinic acid | |
| JP2009269889A (en) | Glutathione production promoter, agent for preventing or treating disease caused by deficiency of glutathione, and food and drink | |
| JP2024026323A (en) | Food composition for enhancing phosphorylated AMP-activated protein kinase expression or phosphorylated acetyl-CoA carboxylase expression, phosphorylated AMP-activated protein kinase expression enhancer, and phosphorylated acetyl-CoA carboxylase expression enhancer | |
| JP2007291081A (en) | Composition having bone resorption inhibition-related effect | |
| JP2010083787A (en) | Cinnamic aldehyde and cassia extract as cb1 receptor antagonist | |
| JP2019208502A (en) | Lifestyle-related disease improvement or prevention food composition | |
| KR101944295B1 (en) | Composition for improving liver function comprising fermentation product of Hovenia dulcis fruit extract | |
| JP2012158573A (en) | Hydroxy fatty acid derivative-containing material and application of the same | |
| JP2011168540A (en) | Anti-obesity action promoter, and adiponectin secretion promoter or inhibitor of reduction in the secretion of adiponectin | |
| AU2013367872B2 (en) | Igf-1 production-promoting agent | |
| JP2023022363A (en) | Cell protection agent | |
| JP6956957B2 (en) | Hair loss inhibitor | |
| JP2018058792A (en) | Pcsk9 inhibitor and food composition for cholesterol metabolism improvement | |
| JP6792753B2 (en) | Ferulic acid derivative-containing composition and method for producing the same | |
| EP3142660B1 (en) | Composition comprising 7-hydroxymatairesinol | |
| JPWO2020004568A1 (en) | Equol production promoter and equol production promoting food or beverage composition containing the same | |
| TWI725464B (en) | The reduced fat probiotic strain, composition thereof and use thereof | |
| KR20190012509A (en) | Composition comprising extract of Angelica decursiva Franchet et Savatieras or compounds isolated therefrom for preventing or treating metabolic bone disease | |
| JP2012180340A (en) | Inhibitor for lowering brain function | |
| KR20120084504A (en) | Pharmaceutical composition for preventing or treating inflammatory diseases comprising sinapic acid | |
| JP2010100551A (en) | Activator of nuclear receptors ppar alpha, ppar delta and rxr | |
| WO2024057782A1 (en) | Agent for improving brain function and composition for improving brain function | |
| KR101629797B1 (en) | Composition comprising Pulsatilla koreana Nakai extract or active ingredient isolated from the same for preventing or treating obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220225 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230425 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230620 |